Metabolomic	B:C1328813
analysis	O
of	O
glycerophospholipid	O
signatures	O
of	O
inflammation	O
treated	O
with	I:C0332293
non-steroidal	O
anti-inflammatory	I:C0003211
drugs	I:C0003211
-	O
induced	O
-	O
RAW264.7	O
cells	I:C0024432
using	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
and	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-MS	O
.	O

Metabolomic	O
analysis	O
of	O
glycerophospholipid	B:C0162448
signatures	O
of	O
inflammation	O
treated	O
with	I:C0332293
non-steroidal	O
anti-inflammatory	I:C0003211
drugs	I:C0003211
-	O
induced	O
-	O
RAW264.7	O
cells	I:C0024432
using	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
and	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-MS	O
.	O

Metabolomic	O
analysis	O
of	O
glycerophospholipid	O
signatures	O
of	O
inflammation	B:C0021368
treated	O
with	I:C0332293
non-steroidal	O
anti-inflammatory	I:C0003211
drugs	I:C0003211
-	O
induced	O
-	O
RAW264.7	O
cells	I:C0024432
using	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
and	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-MS	O
.	O

Metabolomic	O
analysis	O
of	O
glycerophospholipid	O
signatures	O
of	O
inflammation	O
treated	B:C0332293
with	I:C0332293
non-steroidal	O
anti-inflammatory	I:C0003211
drugs	I:C0003211
-	O
induced	O
-	O
RAW264.7	O
cells	I:C0024432
using	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
and	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-MS	O
.	O

Metabolomic	O
analysis	O
of	O
glycerophospholipid	O
signatures	O
of	O
inflammation	O
treated	O
with	I:C0332293
non-steroidal	B:C0003211
anti-inflammatory	I:C0003211
drugs	I:C0003211
-	O
induced	O
-	O
RAW264.7	O
cells	I:C0024432
using	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
and	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-MS	O
.	O

Metabolomic	O
analysis	O
of	O
glycerophospholipid	O
signatures	O
of	O
inflammation	O
treated	O
with	I:C0332293
non-steroidal	O
anti-inflammatory	I:C0003211
drugs	I:C0003211
-	O
induced	O
-	O
RAW264.7	B:C0024432
cells	I:C0024432
using	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
and	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-MS	O
.	O

Metabolomic	O
analysis	O
of	O
glycerophospholipid	O
signatures	O
of	O
inflammation	O
treated	O
with	I:C0332293
non-steroidal	O
anti-inflammatory	I:C0003211
drugs	I:C0003211
-	O
induced	O
-	O
RAW264.7	O
cells	I:C0024432
using	O
(	B:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
and	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-MS	O
.	O

Metabolomic	O
analysis	O
of	O
glycerophospholipid	O
signatures	O
of	O
inflammation	O
treated	O
with	I:C0332293
non-steroidal	O
anti-inflammatory	I:C0003211
drugs	I:C0003211
-	O
induced	O
-	O
RAW264.7	O
cells	I:C0024432
using	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
and	O
U	B:C0008562
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-MS	O
.	O

Non-destructive	B:C0877853
proton	I:C0877853
nuclear	I:C0877853
magnetic	I:C0877853
resonance	I:C0877853
(	I:C0877853
(	I:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
)	I:C0877853
spectroscopy	I:C0877853
and	O
highly	O
sensitive	O
ultra-performance	O
liquid	I:C0008562
chromatography	I:C0008562
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-	O
MS	O
)	O
coupled	O
to	O
data	O
processing	O
methods	O
were	O
applied	O
to	O
analyze	O
the	O
metabolic	O
profiling	I:C1328813
changes	O
of	O
glycerophospholipids	O
(	O
glycerophospholipids	O
)	O
in	O
RAW264.7	O
cells	I:C0024432
from	O
inflammation	O
to	O
prognosis	O
.	O

Non-destructive	O
proton	I:C0877853
nuclear	I:C0877853
magnetic	I:C0877853
resonance	I:C0877853
(	I:C0877853
(	I:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
)	I:C0877853
spectroscopy	I:C0877853
and	O
highly	O
sensitive	O
ultra-performance	B:C0008562
liquid	I:C0008562
chromatography	I:C0008562
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-	O
MS	O
)	O
coupled	O
to	O
data	O
processing	O
methods	O
were	O
applied	O
to	O
analyze	O
the	O
metabolic	O
profiling	I:C1328813
changes	O
of	O
glycerophospholipids	O
(	O
glycerophospholipids	O
)	O
in	O
RAW264.7	O
cells	I:C0024432
from	O
inflammation	O
to	O
prognosis	O
.	O

Non-destructive	O
proton	I:C0877853
nuclear	I:C0877853
magnetic	I:C0877853
resonance	I:C0877853
(	I:C0877853
(	I:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
)	I:C0877853
spectroscopy	I:C0877853
and	O
highly	O
sensitive	O
ultra-performance	O
liquid	I:C0008562
chromatography	I:C0008562
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
U	B:C0008562
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-	O
MS	O
)	O
coupled	O
to	O
data	O
processing	O
methods	O
were	O
applied	O
to	O
analyze	O
the	O
metabolic	O
profiling	I:C1328813
changes	O
of	O
glycerophospholipids	O
(	O
glycerophospholipids	O
)	O
in	O
RAW264.7	O
cells	I:C0024432
from	O
inflammation	O
to	O
prognosis	O
.	O

Non-destructive	O
proton	I:C0877853
nuclear	I:C0877853
magnetic	I:C0877853
resonance	I:C0877853
(	I:C0877853
(	I:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
)	I:C0877853
spectroscopy	I:C0877853
and	O
highly	O
sensitive	O
ultra-performance	O
liquid	I:C0008562
chromatography	I:C0008562
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-	O
MS	O
)	O
coupled	O
to	O
data	O
processing	O
methods	B:C0025663
were	O
applied	O
to	O
analyze	O
the	O
metabolic	O
profiling	I:C1328813
changes	O
of	O
glycerophospholipids	O
(	O
glycerophospholipids	O
)	O
in	O
RAW264.7	O
cells	I:C0024432
from	O
inflammation	O
to	O
prognosis	O
.	O

Non-destructive	O
proton	I:C0877853
nuclear	I:C0877853
magnetic	I:C0877853
resonance	I:C0877853
(	I:C0877853
(	I:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
)	I:C0877853
spectroscopy	I:C0877853
and	O
highly	O
sensitive	O
ultra-performance	O
liquid	I:C0008562
chromatography	I:C0008562
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-	O
MS	O
)	O
coupled	O
to	O
data	O
processing	O
methods	O
were	O
applied	O
to	O
analyze	O
the	O
metabolic	B:C1328813
profiling	I:C1328813
changes	O
of	O
glycerophospholipids	O
(	O
glycerophospholipids	O
)	O
in	O
RAW264.7	O
cells	I:C0024432
from	O
inflammation	O
to	O
prognosis	O
.	O

Non-destructive	O
proton	I:C0877853
nuclear	I:C0877853
magnetic	I:C0877853
resonance	I:C0877853
(	I:C0877853
(	I:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
)	I:C0877853
spectroscopy	I:C0877853
and	O
highly	O
sensitive	O
ultra-performance	O
liquid	I:C0008562
chromatography	I:C0008562
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-	O
MS	O
)	O
coupled	O
to	O
data	O
processing	O
methods	O
were	O
applied	O
to	O
analyze	O
the	O
metabolic	O
profiling	I:C1328813
changes	O
of	O
glycerophospholipids	B:C0162448
(	O
glycerophospholipids	O
)	O
in	O
RAW264.7	O
cells	I:C0024432
from	O
inflammation	O
to	O
prognosis	O
.	O

Non-destructive	O
proton	I:C0877853
nuclear	I:C0877853
magnetic	I:C0877853
resonance	I:C0877853
(	I:C0877853
(	I:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
)	I:C0877853
spectroscopy	I:C0877853
and	O
highly	O
sensitive	O
ultra-performance	O
liquid	I:C0008562
chromatography	I:C0008562
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-	O
MS	O
)	O
coupled	O
to	O
data	O
processing	O
methods	O
were	O
applied	O
to	O
analyze	O
the	O
metabolic	O
profiling	I:C1328813
changes	O
of	O
glycerophospholipids	O
(	O
glycerophospholipids	B:C0162448
)	O
in	O
RAW264.7	O
cells	I:C0024432
from	O
inflammation	O
to	O
prognosis	O
.	O

Non-destructive	O
proton	I:C0877853
nuclear	I:C0877853
magnetic	I:C0877853
resonance	I:C0877853
(	I:C0877853
(	I:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
)	I:C0877853
spectroscopy	I:C0877853
and	O
highly	O
sensitive	O
ultra-performance	O
liquid	I:C0008562
chromatography	I:C0008562
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-	O
MS	O
)	O
coupled	O
to	O
data	O
processing	O
methods	O
were	O
applied	O
to	O
analyze	O
the	O
metabolic	O
profiling	I:C1328813
changes	O
of	O
glycerophospholipids	O
(	O
glycerophospholipids	O
)	O
in	O
RAW264.7	B:C0024432
cells	I:C0024432
from	O
inflammation	O
to	O
prognosis	O
.	O

Non-destructive	O
proton	I:C0877853
nuclear	I:C0877853
magnetic	I:C0877853
resonance	I:C0877853
(	I:C0877853
(	I:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
)	I:C0877853
spectroscopy	I:C0877853
and	O
highly	O
sensitive	O
ultra-performance	O
liquid	I:C0008562
chromatography	I:C0008562
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-	O
MS	O
)	O
coupled	O
to	O
data	O
processing	O
methods	O
were	O
applied	O
to	O
analyze	O
the	O
metabolic	O
profiling	I:C1328813
changes	O
of	O
glycerophospholipids	O
(	O
glycerophospholipids	O
)	O
in	O
RAW264.7	O
cells	I:C0024432
from	O
inflammation	B:C0021368
to	O
prognosis	O
.	O

Non-destructive	O
proton	I:C0877853
nuclear	I:C0877853
magnetic	I:C0877853
resonance	I:C0877853
(	I:C0877853
(	I:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
)	I:C0877853
spectroscopy	I:C0877853
and	O
highly	O
sensitive	O
ultra-performance	O
liquid	I:C0008562
chromatography	I:C0008562
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-	O
MS	O
)	O
coupled	O
to	O
data	O
processing	O
methods	O
were	O
applied	O
to	O
analyze	O
the	O
metabolic	O
profiling	I:C1328813
changes	O
of	O
glycerophospholipids	O
(	O
glycerophospholipids	O
)	O
in	O
RAW264.7	O
cells	I:C0024432
from	O
inflammation	O
to	O
prognosis	B:C0033325
.	O

Analysis	B:C0936012
of	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
was	O
shown	O
that	O
the	O
models	O
were	O
grouped	O
successfully	O
,	O
illustrating	O
that	O
all	O
of	O
them	O
had	O
significant	O
differences	O
.	O

Analysis	O
of	O
(	B:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
was	O
shown	O
that	O
the	O
models	O
were	O
grouped	O
successfully	O
,	O
illustrating	O
that	O
all	O
of	O
them	O
had	O
significant	O
differences	O
.	O

Analysis	O
of	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
was	O
shown	O
that	O
the	O
models	B:C3161035
were	O
grouped	O
successfully	O
,	O
illustrating	O
that	O
all	O
of	O
them	O
had	O
significant	O
differences	O
.	O

Based	O
on	O
the	O
highly	O
simple	O
,	O
accurate	O
,	O
non-targeted	O
and	O
non-destructively	O
advantages	O
of	O
(	B:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
,	O
it	O
could	O
be	O
used	O
as	O
a	O
new	O
screening	O
tool	O
of	O
anti-inflammatory	O
drugs	I:C0003209
in	O
the	O
metabolic	O
profiling	I:C1328813
of	O
glycerophospholipids	O
.	O

Based	O
on	O
the	O
highly	O
simple	O
,	O
accurate	O
,	O
non-targeted	O
and	O
non-destructively	O
advantages	O
of	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
,	O
it	O
could	O
be	O
used	O
as	O
a	O
new	O
screening	O
tool	O
of	O
anti-inflammatory	B:C0003209
drugs	I:C0003209
in	O
the	O
metabolic	O
profiling	I:C1328813
of	O
glycerophospholipids	O
.	O

Based	O
on	O
the	O
highly	O
simple	O
,	O
accurate	O
,	O
non-targeted	O
and	O
non-destructively	O
advantages	O
of	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
,	O
it	O
could	O
be	O
used	O
as	O
a	O
new	O
screening	O
tool	O
of	O
anti-inflammatory	O
drugs	I:C0003209
in	O
the	O
metabolic	B:C1328813
profiling	I:C1328813
of	O
glycerophospholipids	O
.	O

Based	O
on	O
the	O
highly	O
simple	O
,	O
accurate	O
,	O
non-targeted	O
and	O
non-destructively	O
advantages	O
of	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
,	O
it	O
could	O
be	O
used	O
as	O
a	O
new	O
screening	O
tool	O
of	O
anti-inflammatory	O
drugs	I:C0003209
in	O
the	O
metabolic	O
profiling	I:C1328813
of	O
glycerophospholipids	B:C0162448
.	O

58	O
glycerophospholipids	B:C0162448
were	O
identified	O
by	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q-	O
TOF	O
-MS	O
,	O
and	O
19	O
components	O
were	O
firstly	O
identified	O
in	O
this	O
study	O
compared	O
with	O
our	O
previous	O
results	O
.	O

58	O
glycerophospholipids	O
were	O
identified	O
by	O
U	B:C0008562
-	I:C0008562
HPLC	I:C0008562
/	O
Q-	O
TOF	O
-MS	O
,	O
and	O
19	O
components	O
were	O
firstly	O
identified	O
in	O
this	O
study	O
compared	O
with	O
our	O
previous	O
results	O
.	O

58	O
glycerophospholipids	O
were	O
identified	O
by	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q-	O
TOF	O
-MS	O
,	O
and	O
19	O
components	O
were	O
firstly	O
identified	O
in	O
this	O
study	B:C2603343
compared	O
with	O
our	O
previous	O
results	O
.	O

In	O
addition	O
,	O
ten	O
potential	O
biomarkers	B:C0005516
were	O
proved	O
,	O
of	O
which	O
phosphatidylcholine	O
(	O
phosphatidylcholine	O
)	O
(	O
16:0/18:1	O
)	O
and	O
(	O
18:0	O
/	O
18:1	O
)	O
changed	O
consistently	O
in	O
three	O
drug	O
-	O
induced	O
groups	O
and	O
might	O
be	O
the	O
important	O
biomarkers	O
.	O

In	O
addition	O
,	O
ten	O
potential	O
biomarkers	O
were	O
proved	O
,	O
of	O
which	O
phosphatidylcholine	B:C1959616
(	O
phosphatidylcholine	O
)	O
(	O
16:0/18:1	O
)	O
and	O
(	O
18:0	O
/	O
18:1	O
)	O
changed	O
consistently	O
in	O
three	O
drug	O
-	O
induced	O
groups	O
and	O
might	O
be	O
the	O
important	O
biomarkers	O
.	O

In	O
addition	O
,	O
ten	O
potential	O
biomarkers	O
were	O
proved	O
,	O
of	O
which	O
phosphatidylcholine	O
(	O
phosphatidylcholine	B:C1959616
)	O
(	O
16:0/18:1	O
)	O
and	O
(	O
18:0	O
/	O
18:1	O
)	O
changed	O
consistently	O
in	O
three	O
drug	O
-	O
induced	O
groups	O
and	O
might	O
be	O
the	O
important	O
biomarkers	O
.	O

In	O
addition	O
,	O
ten	O
potential	O
biomarkers	O
were	O
proved	O
,	O
of	O
which	O
phosphatidylcholine	O
(	O
phosphatidylcholine	O
)	O
(	O
16:0/18:1	O
)	O
and	O
(	O
18:0	O
/	O
18:1	O
)	O
changed	O
consistently	O
in	O
three	O
drug	O
-	O
induced	O
groups	O
and	O
might	O
be	O
the	O
important	O
biomarkers	B:C0005516
.	O

Compared	O
with	O
(	B:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
,	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q-TOF	O
-MS	O
showed	O
higher	O
sensitivity	O
and	O
specificity	O
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	O
of	O
biomarkers	O
apart	O
from	O
the	O
deficiency	O
of	O
time	O
-	O
consuming	O
sample	O
preparation	I:C1720914
steps	I:C1720914
and	O
unambiguous	O
metabolite	O
identification	O
.	O

Compared	O
with	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
,	O
U	B:C0008562
-	I:C0008562
HPLC	I:C0008562
/	O
Q-TOF	O
-MS	O
showed	O
higher	O
sensitivity	O
and	O
specificity	O
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	O
of	O
biomarkers	O
apart	O
from	O
the	O
deficiency	O
of	O
time	O
-	O
consuming	O
sample	O
preparation	I:C1720914
steps	I:C1720914
and	O
unambiguous	O
metabolite	O
identification	O
.	O

Compared	O
with	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
,	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q-TOF	O
-MS	O
showed	O
higher	O
sensitivity	O
and	O
specificity	O
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	B:C1148554
of	O
biomarkers	O
apart	O
from	O
the	O
deficiency	O
of	O
time	O
-	O
consuming	O
sample	O
preparation	I:C1720914
steps	I:C1720914
and	O
unambiguous	O
metabolite	O
identification	O
.	O

Compared	O
with	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
,	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q-TOF	O
-MS	O
showed	O
higher	O
sensitivity	O
and	O
specificity	O
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	O
of	O
biomarkers	B:C0005516
apart	O
from	O
the	O
deficiency	O
of	O
time	O
-	O
consuming	O
sample	O
preparation	I:C1720914
steps	I:C1720914
and	O
unambiguous	O
metabolite	O
identification	O
.	O

Compared	O
with	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
,	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q-TOF	O
-MS	O
showed	O
higher	O
sensitivity	O
and	O
specificity	O
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	O
of	O
biomarkers	O
apart	O
from	O
the	O
deficiency	O
of	O
time	O
-	O
consuming	O
sample	B:C1720914
preparation	I:C1720914
steps	I:C1720914
and	O
unambiguous	O
metabolite	O
identification	O
.	O

Compared	O
with	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
,	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q-TOF	O
-MS	O
showed	O
higher	O
sensitivity	O
and	O
specificity	O
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	O
of	O
biomarkers	O
apart	O
from	O
the	O
deficiency	O
of	O
time	O
-	O
consuming	O
sample	O
preparation	I:C1720914
steps	I:C1720914
and	O
unambiguous	O
metabolite	B:C0870883
identification	O
.	O

Therefore	O
,	O
it	O
is	O
feasible	O
to	O
analyze	O
the	O
changes	O
of	O
glycerophospholipids	B:C0162448
during	O
inflammation	O
by	O
combining	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
spectroscopy	I:C0877853
with	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-MS	O
.	O

Therefore	O
,	O
it	O
is	O
feasible	O
to	O
analyze	O
the	O
changes	O
of	O
glycerophospholipids	O
during	O
inflammation	B:C0021368
by	O
combining	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
spectroscopy	I:C0877853
with	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-MS	O
.	O

Therefore	O
,	O
it	O
is	O
feasible	O
to	O
analyze	O
the	O
changes	O
of	O
glycerophospholipids	O
during	O
inflammation	O
by	O
combining	O
(	B:C0877853
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
spectroscopy	I:C0877853
with	O
U	O
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-MS	O
.	O

Therefore	O
,	O
it	O
is	O
feasible	O
to	O
analyze	O
the	O
changes	O
of	O
glycerophospholipids	O
during	O
inflammation	O
by	O
combining	O
(	O
1	I:C0877853
)	I:C0877853
H	I:C0877853
NMR	I:C0877853
spectroscopy	I:C0877853
with	O
U	B:C0008562
-	I:C0008562
HPLC	I:C0008562
/	O
Q	O
-	O
TOF	O
-MS	O
.	O

The	O
metabolic	B:C1328813
profiling	I:C1328813
of	O
glycerophospholipids	O
provides	O
valuable	O
evidence	O
for	O
inflammation	O
diagnosis	O
and	O
prognosis	O
,	O
and	O
might	O
unravel	O
the	O
mechanisms	O
involved	O
in	O
inflammation	O
progression	O
.	O

The	O
metabolic	O
profiling	I:C1328813
of	O
glycerophospholipids	B:C0162448
provides	O
valuable	O
evidence	O
for	O
inflammation	O
diagnosis	O
and	O
prognosis	O
,	O
and	O
might	O
unravel	O
the	O
mechanisms	O
involved	O
in	O
inflammation	O
progression	O
.	O

The	O
metabolic	O
profiling	I:C1328813
of	O
glycerophospholipids	O
provides	O
valuable	O
evidence	O
for	O
inflammation	B:C0021368
diagnosis	O
and	O
prognosis	O
,	O
and	O
might	O
unravel	O
the	O
mechanisms	O
involved	O
in	O
inflammation	O
progression	O
.	O

The	O
metabolic	O
profiling	I:C1328813
of	O
glycerophospholipids	O
provides	O
valuable	O
evidence	O
for	O
inflammation	O
diagnosis	B:C0011900
and	O
prognosis	O
,	O
and	O
might	O
unravel	O
the	O
mechanisms	O
involved	O
in	O
inflammation	O
progression	O
.	O

The	O
metabolic	O
profiling	I:C1328813
of	O
glycerophospholipids	O
provides	O
valuable	O
evidence	O
for	O
inflammation	O
diagnosis	O
and	O
prognosis	B:C0033325
,	O
and	O
might	O
unravel	O
the	O
mechanisms	O
involved	O
in	O
inflammation	O
progression	O
.	O

The	O
metabolic	O
profiling	I:C1328813
of	O
glycerophospholipids	O
provides	O
valuable	O
evidence	O
for	O
inflammation	O
diagnosis	O
and	O
prognosis	O
,	O
and	O
might	O
unravel	O
the	O
mechanisms	O
involved	O
in	O
inflammation	B:C0021368
progression	O
.	O

The	O
metabolic	O
profiling	I:C1328813
of	O
glycerophospholipids	O
provides	O
valuable	O
evidence	O
for	O
inflammation	O
diagnosis	O
and	O
prognosis	O
,	O
and	O
might	O
unravel	O
the	O
mechanisms	O
involved	O
in	O
inflammation	O
progression	B:C0242656
.	O

